Ændring i ALK’s bestyrelse
05 août 2021 04h23 HE
|
ALK Abello
Bestyrelsen for ALK-Abelló A/S (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddeler i dag, at den vil indstille Alan Main, tidligere direktør for Consumer Healthcare i Sanofi, som uafhængigt medlem af...
Release date of six-month interim report (Q2) 2021 for ALK and audio cast
05 août 2021 02h32 HE
|
ALK Abello
On Wednesday, 11 August 2021, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its six-month interim report (Q2) 2021. ALK will host a meeting for analysts and institutional investors that day at...
Dato for offentliggørelse af delårsrapport for første halvår (Q2) 2021 for ALK og webcast
05 août 2021 02h32 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første halvår (Q2) 2021 onsdag den 11. august 2021. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for...
ALK and Grandpharma team up to market the first adrenaline autoinjector in China
30 juil. 2021 08h51 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) to launch its adrenaline autoinjector (AAI), Jext®, in China via a partnership with leading supplier of adrenaline, Grandpharma.Jext® is expected to be the...
ALK og Grandpharma indgår partnerskab om markedsføring af den første adrenalinpen i Kina
30 juil. 2021 08h51 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) vil lancere Jext® i Kina via et partnerskab med den førende leverandør af adrenalin, Grandpharma.Jext® forventes at blive den første adrenalinpen på det...
New, large, ‘real-world evidence’ study by ALK of AIT’s long-term effects on allergy and asthma presented at EAACI Congress
10 juil. 2021 05h35 HE
|
ALK Abello
Leading allergy researchers present data from a new, large, ‘real-world evidence’ study of allergy immunotherapy at EAACI Annual Congress in Krakow, PolandStudy assessed long-term outcomes in allergic...
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer
10 mai 2021 11h25 HE
|
ALK Abello
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af...
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
10 mai 2021 11h25 HE
|
ALK Abello
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No...
Three-month interim report (Q1) 2021
05 mai 2021 00h57 HE
|
ALK Abello
Bemærk venligst, at rapporten foreligger udelukkende på engelsk. ALK reports 9% sales growth in Q1 fuelled by better than expected tablet growth of 32% (unaudited) The first three months of 2021...
Three-month interim report (Q1) 2021
05 mai 2021 00h57 HE
|
ALK Abello
ALK reports 9% sales growth in Q1 fuelled by better than expected tablet growth of 32% (unaudited) The first three months of 2021 represented ALK’s best-ever quarter, with revenue exceeding DKK 1...